Interviews of 2021: spermidine, placentas and clinical trial lessons

Five of our favourite interviews with some of the world’s leading researchers from across the aging field.

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Five of our favourite interviews with the longevity entrepreneurs behind companies targeting aging.

We interviewed hundreds of thought leaders from across the longevity ecosystem in 2021, and so it’s with misty-eyed nostalgia that we now reflect on some of the highlights from the past year. This article focuses on some of the entrepreneurs we spoke to, covering subjects ranging from the power of the placenta and mitochondria, to spermidine supplements and clinical trial failure.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

Danny Sullivan

Danny has worked in technology communications for more than 20 years, and has been writing about developments the longevity sector since 2019. With a keen interest in the transfer of technology to market, he focuses primarily on the companies working on cutting-edge solutions to aging and age-related diseases.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Oura spends $625m to put doctors behind its smart ring

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE